<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">The use of HIPEC is considered as a potential prophylactic approach to avoid peritoneal recurrence of cancer. Nevertheless, data about prophylactic HIPEC in gastric cancer is scarce, and it is difficult to outline its role against peritoneal recurrence. In this study, we evaluated the post-operational complications and outcomes of gastric cancer patients who underwent radical gastrectomy followed by HIPEC with cisplatin, focusing our analysis on the safety and tolerability of the experimental treatment, which could influence patient survival.</p>
